3,5-diamino-N-carbamimidoyl-6-(2-phenylethynyl)pyrazine-2-carboxamide;hydrochloride | 1345839-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3,5-diamino-N-carbamimidoyl-6-(2-phenylethynyl)pyrazine-2-carboxamide;hydrochloride
• CAS: 1345839-41-9
• 化学式: C₁₄H₁₃N₇O*ClH
• 分子量: 331.764
• InChiKey: MNIBJACCFUUFOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.12
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  159
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,5-二氨基-6-碘吡嗪-2-羧酸甲酯 在 copper(l) iodide 、 四(三苯基膦)钯 、 sodium 、 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 生成 3,5-diamino-N-carbamimidoyl-6-(2-phenylethynyl)pyrazine-2-carboxamide;hydrochloride
  参考文献：
  名称：

  Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)

  摘要：

  A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K-i = 7 mu M), a promising anticancer target. Several studies have demonstrated significant antitumor/metastasis properties for amiloride in animal cancer models and it would appear that these arise, at least in part, through inhibition of uPA. Selective optimization of amiloride's structure for more potent inhibition of uPA and loss of diuretic effects would thus appear as an attractive strategy towards novel anticancer agents. The following report is a preliminary structure-activity exploration of amiloride analogs as inhibitors of uPA. A key finding was that the well-studied 5-substituted analogs ethylisopropyl amiloride (EIPA) and hexamethylene amiloride (HMA) are approximately twofold more potent than amiloride as uPA inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.044

文献信息

• Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR
  作者：Neeraj N. Patwardhan、Laura R. Ganser、Gary J. Kapral、Christopher S. Eubanks、Janghyun Lee、Bharathwaj Sathyamoorthy、Hashim M. Al-Hashimi、Amanda E. Hargrove

  DOI：10.1039/c6md00729e

  日期：——

  dimethylamiloride from a weak TAR ligand to one of the tightest binding selective TAR ligands reported to date through a novel combination of synthetic methods and analytical techniques. We expect these methods to allow for rapid library expansion and tuning of the amiloride scaffold for a range of RNA targets and for SOFAST NMR to allow unprecedented evaluation of small molecule:RNA interactions.

  RNA靶向支架的多样化为寻找治疗相关RNA（例如HIV-1 TAR）的选择性配体提供了广阔的前景。我们在此报告了阿米洛利作为一种新型的RNA结合支架，以及合成的C（5）-和C（6）-多样化途径的合成途径的建立。在C（5）-和C（6）位置的迭代修饰产生衍生物24，在肽置换试验中，其活性比母体二甲基阿米洛利提高了100倍。使用2D SOFAST- [ 1 H- 13C] HMQC NMR方法，可以轻松快速地评估所有文库成员的结合模式。化学信息学分析揭示了选择性配体和非选择性配体之间的明显差异。在这项研究中，我们通过合成方法和分析技术的新颖结合，将二甲基阿米洛利从弱的TAR配体演化为迄今为止报道的结合最紧密的选择性TAR配体之一。我们希望这些方法能够快速扩增文库并调整阿米洛利支架的RNA靶标范围，并对SOFAST NMR进行前所未有的小分子与RNA相互作用的评估。